# A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

> **NCT07376642** · EARLY_PHASE1 · RECRUITING · sponsor: **Suzhou Immunofoco Biotechnology Co., Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** IMV101 treatment

## Key facts

- **NCT ID:** NCT07376642
- **Lead sponsor:** Suzhou Immunofoco Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-29
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07376642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07376642, "A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07376642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*